USANA Health Sciences, Inc. Common Stock (USNA)
Healthcare › Medicinal Chemicals & Botanical Products
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 26% below Graham Number ($28.04) — significant margin of safety
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 4.4% — below-average profitability
- Revenue growing at 8% annually
USANA Health Sciences, Inc. Common Stock (USNA) is a Healthcare company operating in Medicinal Chemicals & Botanical Products, listed on the NYSE , with a market capitalisation of $382 million . Key value metrics: P/E ratio 19.1, P/B ratio 0.75, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
USANA Health Sciences, Inc. Common Stock — Fundamental Analysis Summary
USANA Health Sciences, Inc. Common Stock (USNA) is trading 26% below its Graham Number of $28.04 — a significant margin of safety by Benjamin Graham's standard. The stock carries a reasonable trailing P/E ratio of 19.1x.
On financial health, USNA shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 4.4% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.27.
StockPik's composite Value Score for USNA is 77/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
USNA reports a high gross margin of 77.8% (sector average: 39.4%) and a modest operating margin of 5.0%.
USNA shows revenue growing at 8% year-over-year, with earnings declining at 74%.